N-16 Solution
NDC Package 58264-0214-1
Package Information
N-16 (mgo energizer) solution is a medication used as Multiple gland and organ support. This formulation utilizes a solution delivery system. Marketed by Dna Labs, Inc., this product is identified by NDC 58264-0214.
Identification & Billing
Clinical Specifications
- ASCORBIC ACID 3 [hp_X]/mL
- BEEF HEART 200 [hp_X]/mL
- BOS TAURUS ADRENAL GLAND 200 [hp_X]/mL
- BOS TAURUS PITUITARY GLAND, POSTERIOR 200 [hp_X]/mL
- BOS TAURUS THYMUS 200 [hp_X]/mL
- CALCIUM FLUORIDE 30 [hp_X]/mL
- CALCIUM SULFATE ANHYDROUS 30 [hp_X]/mL
- DIBASIC POTASSIUM PHOSPHATE 30 [hp_X]/mL
- FERROSOFERRIC PHOSPHATE 30 [hp_X]/mL
- GLYCINE 4 [hp_X]/mL
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE 30 [hp_X]/mL
- MAMMAL LIVER 200 [hp_X]/mL
- PORK BRAIN 200 [hp_X]/mL
- POTASSIUM CHLORIDE 30 [hp_X]/mL
- POTASSIUM SULFATE 30 [hp_X]/mL
- PYRIDOXINE HYDROCHLORIDE 3 [hp_X]/mL
- SILICON DIOXIDE 30 [hp_X]/mL
- SODIUM CHLORIDE 30 [hp_X]/mL
- SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 30 [hp_X]/mL
- SODIUM SULFATE 30 [hp_X]/mL
- SUS SCROFA DUODENUM 200 [hp_X]/mL
- SUS SCROFA LUNG 200 [hp_X]/mL
- SUS SCROFA PANCREAS 200 [hp_X]/mL
- SUS SCROFA SPLEEN 200 [hp_X]/mL
- THYROID, UNSPECIFIED 200 [hp_X]/mL
- TRIBASIC CALCIUM PHOSPHATE 30 [hp_X]/mL
- TRIPE 200 [hp_X]/mL
- Analogs/Derivatives - [Chemical/Ingredient]
- Ascorbic Acid - [CS]
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Phosphate Binder - [EPC] (Established Pharmacologic Class)
- Phosphate Chelating Activity - [MoA] (Mechanism of Action)
- Potassium Compounds - [CS]
- Potassium Salt - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
- Vitamin B 6 - [Chemical/Ingredient]
- Vitamin B6 Analog - [EPC] (Established Pharmacologic Class)
- Vitamin C - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 58264 - Dna Labs, Inc.
- 58264-0214 - N-16
- 58264-0214-1 - 29.57 mL in 1 BOTTLE, GLASS
- 58264-0214 - N-16
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 58264-0214-1 identifies a specific commercial package of 29.57 ml in 1 bottle, glass of N-16, a human over the counter drug labeled by Dna Labs, Inc.. This solution is formulated for sublingual use and contains ascorbic acid; beef heart; bos taurus adrenal gland; bos taurus pituitary gland, posterior; bos taurus thymus; calcium fluoride; calcium sulfate anhydrous; dibasic potassium phosphate; ferrosoferric phosphate; glycine; magnesium phosphate, dibasic trihydrate; mammal liver; pork brain; potassium chloride; potassium sulfate; pyridoxine hydrochloride; silicon dioxide; sodium chloride; sodium phosphate, dibasic, heptahydrate; sodium sulfate; sus scrofa duodenum; sus scrofa lung; sus scrofa pancreas; sus scrofa spleen; thyroid, unspecified; tribasic calcium phosphate; tripe as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dna Labs, Inc. on January 01, 1990. The current certification is valid through December 31, 2026.
How is this Dna Labs, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 58264021401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.